BioCentury
ARTICLE | Company News

GlaxoSmithKline sales and marketing update

June 8, 2015 7:00 AM UTC

The German Institute for Quality and Efficiency in Health Care (IQWiG) said Tanzeum albiglutide from GlaxoSmithKline in combination with metformin has a “hint of a minor added benefit” in patients with Type II diabetes vs. glimepiride and metformin. The agency said the Tanzeum arm experienced fewer non-serious/non-severe adverse events but noted that Tanzeum is injected while glimepiride is taken orally.

The agency also determined that there was no added benefit for three additional subindications for which the pharma did not provide relevant data, including Tanzeum monotherapy, Tanzeum with at least two other blood-glucose lowering drugs and Tanzeum in combination with insulin. ...